Defense World
14 Mar 2026, 05:14 UTC · 32w ago
Verdict
Headline leans bullish. We score AVTX +0.40 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.40moderately bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Avalo Therapeutics expects to report top-line data from its Phase 2b LOTUS trial of AVTX-009 in the second quarter.
More positive than 93% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 66% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 66% of ticker scores this week
The company provided a clear timeline for reporting Phase 2b clinical trial data and outlined operational milestones for 2025.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−56.1%
Price is moving against the score
$6.93 vs $15.80 close before publication (Mar 13) · not market-adjusted
AVTX chart →
